Skip to content
2000
Volume 21, Issue 13
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Selegiline (1) [(-)-deprenyl] is used to treat patients with Parkinson’s disease. Nevertheless, in much higher doses it has beneficial effects in depression, and dementia of the aged patients. Selegiline (1) undergoes a complex metabolic pathway. Its major metabolites include (-)-desmethyldeprenyl (2), (-)-methamphetamine (3) and (-)-amphetamine (4), deprenyl-N-oxide (5) and formaldehyde (6) as a small metabolic fragment. In addition, more than 40 minor metabolites of selegiline (1) have also been either detected or proposed by investigators and researchers. This review analyses the pharmacological activity, generation pathway and the detection method of the major metabolites of selegiline (1).

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867321666131218094352
2014-04-01
2025-06-25
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867321666131218094352
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test